Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Debt Ratio (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Debt Ratio for 9 consecutive years, with 0.09 as the latest value for Q4 2023.

  • On a quarterly basis, Debt Ratio fell 41.39% to 0.09 in Q4 2023 year-over-year; TTM through Dec 2023 was 0.09, a 41.39% decrease, with the full-year FY2023 number at 0.09, down 41.39% from a year prior.
  • Debt Ratio was 0.09 for Q4 2023 at Cartesian Therapeutics, down from 0.17 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.53 in Q3 2019 to a low of 0.09 in Q4 2023.
  • A 5-year average of 0.2 and a median of 0.16 in 2021 define the central range for Debt Ratio.
  • Peak YoY movement for Debt Ratio: soared 58.9% in 2019, then tumbled 74.33% in 2020.
  • Cartesian Therapeutics' Debt Ratio stood at 0.19 in 2019, then dropped by 21.07% to 0.15 in 2020, then grew by 6.98% to 0.16 in 2021, then dropped by 1.26% to 0.16 in 2022, then tumbled by 41.39% to 0.09 in 2023.
  • Per Business Quant, the three most recent readings for RNAC's Debt Ratio are 0.09 (Q4 2023), 0.17 (Q2 2023), and 0.17 (Q1 2023).